Clinical Report: Efficacy of Ivarmacitinib for Refractory Primary Cutaneous Amyloidosis

Overview

Revise to include more details about the patient's treatment history and response.

Background

Primary cutaneous amyloidosis (PCA) is a chronic skin disorder characterized by intense itching and the accumulation of amyloid proteins in the skin. Current treatment options are limited and often ineffective, leading to a significant burden on patients' quality of life. The introduction of targeted therapies like ivarmacitinib may offer new hope for patients who do not respond to conventional treatments.

Data Highlights

No numerical data available in the article.

Key Findings

• Ivarmacitinib led to a rapid reduction in pruritus within 24 hours.
• Complete resolution of pruritus was achieved within one week of treatment.
• Marked flattening and lightening of hyperpigmented papules were observed over subsequent weeks.
• No adverse effects were reported during follow-up after treatment with ivarmacitinib.
• The case suggests that targeting the JAK/STAT pathway may be effective in managing refractory PCA.

Clinical Implications

The findings suggest that ivarmacitinib could be a viable treatment option for patients with refractory PCA, particularly those who have not responded to standard therapies. Clinicians should consider the potential benefits of JAK1 inhibition in similar cases of chronic pruritic dermatoses.

Conclusion

Ivarmacitinib shows promise as an effective and well-tolerated treatment for refractory primary cutaneous amyloidosis, warranting further investigation in larger clinical trials.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. The ASCO Post, 2026 -- Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
3. ScienceDirect, 2025 -- Nemolizumab for treatment of lichen amyloidosis
4. the asco post — Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis
5. The ASCO Post — Study Findings on Novel Agents in Neoplastic Hematology
6. Blood Cancer Journal — Results of the MUKeight Phase II Randomized Controlled Trial on Ixazomib Combined with Cyclophosphamide and Dexamethasone for Relapsed or Refractory Myeloma
7. Systematic review and meta-analysis of treatments and outcomes in primary localized cutaneous amyloidosis
8. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial
9. Nemolizumab for treatment of lichen amyloidosis - ScienceDirect